(Q38064066)

28 August 2017

1 reference

title

Implementation of human papillomavirus immunization in the developing world (English)

1 reference

28 August 2017

0 references

3

Silvia de Sanjosé

0 references

author name string

Mark A Kane

series ordinal

1

1 reference

28 August 2017

Beatriz Serrano

series ordinal

2

1 reference

28 August 2017

Scott Wittet

series ordinal

4

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 November 2012

1 reference

28 August 2017

1 reference

28 August 2017

volume

30 Suppl 5

1 reference

28 August 2017

page(s)

F192-200

1 reference

Worldwide burden of cervical cancer in 2008.

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.075

Upgrading public health programs for human papillomavirus prevention and control is possible in low- and middle-income countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.075

Human papillomavirus vaccine introduction--the first five years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.075

Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.075

Strategies to vaccinate against cancer of the cervix: feasibility of a school-based HPV vaccination program in Peru.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.075

Introduction of human papillomavirus vaccines into developing countries - international strategies for funding and procurement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.075

Global implementation of human papillomavirus (HPV) vaccine: lessons from hepatitis B vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.075

Chapter 2: The burden of HPV-related cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.075

EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.075

For cancers caused by HPV, two vaccines were just the beginning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.075

Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.075

Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.075

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.075

Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.075

Formative research to shape HPV vaccine introduction strategies in Peru.

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.075

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.075

inferred from DOI database lookup

7 January 2021

based on heuristic

Human papillomavirus vaccine introduction in Vietnam: formative research findings

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.075

Human papillomavirus vaccine and behavioural disinhibition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.075

Sociocultural issues in the introduction of human papillomavirus vaccine in low-resource settings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.075

The American Medical Association Guidelines for Adolescent Preventive Services

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.075

Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.075

The HPV vaccine controversy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.075

Global safety of vaccines: strengthening systems for monitoring, management and the role of GACVS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.075

Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.075

Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.075

Modeling preventative strategies against human papillomavirus-related disease in developed countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.075

Aspects of prophylactic vaccination against cervical cancer and other human papillomavirus-related cancers in developing countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.075

Surveillance of congenital rubella in Great Britain, 1971-96.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.075

10.1016/J.VACCINE.2012.06.075

7 January 2021

Identifiers

DOI

1 reference

28 August 2017

1 reference